MeMed Diagnostics, Ltd.

Based in Israel, MeMed Diagnostics, Ltd. specializes in advanced diagnostic solutions that utilize machine learning to analyze immune system responses, focusing on rapid differentiation between infections. Founded in 2009 in Tirat Carmel, Israel, MeMed Diagnostics, Ltd. develops diagnostic technologies aimed at improving infectious disease management.

The company has engaged in 8 funding deals, with the latest round in January 2022, raising USD 93. 00 mn led by Horizons Ventures. Co-founders Eran Eden and Kfir Oved continue to lead the company, with Eran Eden serving as CEO. MeMed Ltd.

specializes in advanced diagnostic solutions that leverage machine learning to analyze the immune system's complex signaling. The company’s flagship product, MeMed BV®, is the first FDA-cleared host-immune response assay, designed to differentiate between bacterial and viral infections within 15 minutes. Additionally, the MeMed Key platform facilitates rapid multiplexed protein measurements, enabling healthcare providers to make informed decisions regarding acute infections. Together, these products address critical challenges in infectious diseases and inflammatory disorders, significantly reducing the risk of inappropriate antibiotic prescriptions.

MeMed primarily serves healthcare institutions, including hospitals and pediatric departments, across multiple geographical markets, including the United States, Europe, and Israel, enhancing their clinical decision-making capabilities. MeMed generates revenue through the sale of its diagnostic products, primarily focusing on B2B transactions with hospitals and healthcare facilities. The company offers its products on a transactional basis, likely involving bulk purchases or long-term agreements with healthcare providers. The specific pricing structure for their flagship products, such as MeMed BV® and MeMed Key, is not disclosed; however, it is expected that pricing strategies reflect the advanced technology and rapid diagnostic capabilities they provide.

By facilitating quicker and more accurate diagnoses, MeMed's offerings aim to support healthcare professionals in managing patient care more effectively, ultimately contributing to improved patient outcomes and responsible antibiotic stewardship. In January 2022, MeMed Diagnostics, Ltd. raised USD 93. 00 mn in venture funding, which the company will utilize to commercialize its technology that decodes the body’s immune response.

The firm plans to introduce new products designed to enhance diagnostic capabilities and expand its reach into additional markets, specifically targeting the United States and Europe by 2024.